StockNews.com lowered shares of Oramed Pharmaceuticals (NASDAQ:ORMP – Free Report) from a buy rating to a hold rating in a report published on Monday morning.
Separately, HC Wainwright reissued a “neutral” rating on shares of Oramed Pharmaceuticals in a research report on Monday, September 9th.
Check Out Our Latest Research Report on ORMP
Oramed Pharmaceuticals Trading Up 0.6 %
Oramed Pharmaceuticals (NASDAQ:ORMP – Get Free Report) last announced its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.21. On average, sell-side analysts predict that Oramed Pharmaceuticals will post 0.24 EPS for the current year.
Institutional Trading of Oramed Pharmaceuticals
Large investors have recently bought and sold shares of the stock. XTX Topco Ltd bought a new position in shares of Oramed Pharmaceuticals during the second quarter valued at $40,000. Virtu Financial LLC bought a new position in Oramed Pharmaceuticals during the 1st quarter valued at about $68,000. Dimensional Fund Advisors LP boosted its position in Oramed Pharmaceuticals by 52.1% in the second quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock valued at $81,000 after buying an additional 10,774 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Oramed Pharmaceuticals during the third quarter worth about $272,000. Finally, Renaissance Technologies LLC grew its stake in Oramed Pharmaceuticals by 89.0% during the second quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock worth $593,000 after buying an additional 108,700 shares during the last quarter. 12.73% of the stock is currently owned by institutional investors.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.
Further Reading
- Five stocks we like better than Oramed Pharmaceuticals
- What is Short Interest? How to Use It
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- 3 Warren Buffett Stocks to Buy Now
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.